Unknown PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT01647672

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

A Study to Assess the Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in the Treatment of Operable Breast Cancer

Sponsor: Tianjin Medical University

Conditions Breast Cancer

Interventions Abraxane

Updated 6 times since 2017 Last updated: Jul 24, 2012 Started: Jan 31, 2012 Primary completion: Dec 31, 2012 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Breast Cancer and is currently ongoing. Tianjin Medical University leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University

Data source: Tianjin Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China